Comparison of efficacy and safety of topical hydroquinone 2% and oral tranexamic acid 500 mg in patients of melasma
DOI:
https://doi.org/10.66344/jpad.27.3.2017.1112Keywords:
Melasma, tranexamic acid, hydroquinone, efficacy, MASI scoreAbstract
Objective To compare the efficacy of topical hydroquinone 2% and oral tranexamic acid 500mg daily in patients of melasma. Methods A total of 140 patients (70 patients in each group) were enrolled, who were randomly divided into 2 groups. Group A was treated with topical hydroquinone 2% and group B was given oral tranexamic acid 500mg daily. Follow-up was carried out at the end of 2nd, 4th and 8th week to compare reduction in MASI score at last follow-up. Results The mean age of patients was 29.67 ± 6.38 years with an age range of 15 to 45 years. There were 28 (20%) male and 112 (80%) female patients. Majority i.e. 120 (85.7%) cases were married and 20 (14.3%) were unmarried. The age of onset was 15-25 years in 67 (47.9%) patients, 26-35 years in 52 (37.14%) and 36-45 years in 21(15%) patients. Both groups showed a decline in MASI score; however, the results were significantly greater in group B (oral tranexamic acid). At final follow-up, the mean percentage reduction was higher in group B (77.97±8.37) as compared to group A (67.02±8.42), p < 0.001. Adverse effects like erythema, burning, allergic contact dermatitis and pigmentation were noticed in the first group. One (1.4%) patient developed nausea and vomiting and diarrhea with oral tranexamic acid. Conclusion Oral tranexamic acid 500 mg had a better response when compared with topical hydroquinone 2% cream and better safety profile. It might be considered as a future treatment option.ÂReferences
Damevska K. New Aspects of Melasma. Serbian J Dermatol Venereol. 2014;6:5-18.
Lee A-Y. An updated review of melasma pathogenesis. Dermatologica Sinica. 2014;32:233-9.
Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048-65.
Pawaskar MD, Parikh P, Markowski T, Mcmichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on healthâ€related quality of life in Hispanic women. J Dermatolog Treat. 2007;18:5-9.
Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254.
Rao DS, Shankar K, Somani VK, Kohli M, Sharad J, Ganjoo A et al. A cross-sectional, multicentric clinico-epidemiological study of melasma in India. Dermatol Ther. 2014;4:71-81.
Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28:77-85.
Levin CY, Maibach H. Exogenous ochronosis. Am J Clin Dermatol. 2001;2:213-7.
Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis. 2008;81:365-7.
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54:303.
Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12:57-66.
Maeda K, Naganuma M. Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol B. 1998;47:136-41.
Hashimoto K, Prystowsky JH, Baird J, Lazarus GS, Jensen PJ. Keratinocyte urokinase-type plasminogen activator is secreted as a single chain precursor. J Invest Dermatol. 1988;90:823-8.
Karn D, KC S, Amatya A, Razouria E, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J. 2012;10:40-3.
Cho HH, Choi M, Cho S, Lee JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd: YAG laser. J Dermatolog Treat. 2013;24:292-6.
Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, Pan L. Treatment of melasma with oral administration of tranexamic acid. Aesth Plast Surg. 2012;36:964-70.
Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60:520.
Kim MS, Bang SH, Kim J-H, Shin H-J, Choi H, Chang SE. Tranexamic acid diminishes laser-induced melanogenesis. Ann Dermatol. 2015;27:250-6.
Navarrete-SolÃs J, Castanedo-Cázares JP, Torres-Ãlvarez B, Oros-Ovalle C, Fuentes-Ahumada C, González FJ et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Prac. 2011;21;2011.
Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A comparative study of the efficacy of 4% hydroquinone vs 0.75% Kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013;58:157.
Chowdhury WK, Wahab MA, Khondker L, Khan MS, Shirajul IK. Efficacy and safety of hydroquinone, kojic acid and glycolic acid combination in the treatment of melasma. Bangladesh J Med Sci. 2012;11:191.
Sadako N. Treatment of melasma with tranexamic acid. Clin Represent. 1979;13:3129-31.
Hajime, M., Mineo, T., Yoshio T. Oral administration therapy with tranexamic acid for melasma. Nishinihon J Dermatol. 1985;47:1101-14. (Japanese).
Higashi N. Treatment of melasma with oral tranexamic acid. Skin Res. 1988;30:676-80. (Japanese).
Zhu HJ, Yang XH. The clinical study of acidum tranexamicum on melasma. Pharmacol Prog. 2001;3:178-81.
Liu H, Kou CC, Yeung CW. Effectiveness of tranexamic acid in treating melasma and observation of its safety. Chin J Med Aesth Cosmet. 2005;11:361-3).
Wu SF, Shi HY, Chen Y, Yan Sh CD, Guo J. Treatment of melasma with oral administration of tranexamic acid. Chinese J Aesth Plast Surg. 2008;2:10.
Mafune E, Morimoto Y, Iizuka Y. Tranexamic acid and melasma. Farumashia. 2008;44:437-42.
Cho HH, Choi M, Cho S, Lee JH. (2013) Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd: YAG laser. Journal of Dermatological Treatment. 24. p. 292-296.
Aamir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study. Journal of Pakistan Association of Dermatology. 2016 Dec 2;24(3):198-203.)
Tan AW, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2017;58:e105-e108.
Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75:385-92.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
